Oliver  Engert net worth and biography

Oliver Engert Biography and Net Worth

Insider of Enovis

Chief Administrative Officer, Oliver Engert, is responsible for developing our long-term strategy, driving organizational efficiency and enhancing operational excellence to support profitable, capital-efficient growth.

Prior to joining Enovis, Oliver spent more than 30 years at McKinsey & Company where he advised some of the most iconic medical device companies on their most pressing challenges and biggest opportunities. During his tenure at the firm, he held progressive senior leadership positions – finishing his time there as Senior Partner Emeritus – where he gained extensive experience advising CEOs, other C-suite executives, and boards of directors on strategy, transformations, mergers and acquisitions, organizational design, and performance improvement to deliver significant shareholder value.

In addition to his expertise as a long-standing Life Sciences Partner, Oliver is a globally recognized expert on mergers and acquisitions (M&A), founding McKinsey’s Practice serving all industries. He grew it from 14 colleagues in 2007 to 850+ in 2024. He also established what is now the 32-member McKinsey M&A Council, a cross-sector group of senior M&A executives from around the world.

Oliver has a bachelor’s degree in economics from the Wharton School, University of Pennsylvania, and an MBA from the Amos Tuck School of Business, Dartmouth College.

What is Oliver Engert's net worth?

The estimated net worth of Oliver Engert is at least $1.09 million as of March 3rd, 2026. Engert owns 44,640 shares of Enovis stock worth more than $1,093,234 as of March 6th. This net worth approximation does not reflect any other assets that Engert may own. Learn More about Oliver Engert's net worth.

How do I contact Oliver Engert?

The corporate mailing address for Engert and other Enovis executives is 2711 Centerville Road Suite 400, Wilmington DE, 19808. Enovis can also be reached via phone at 302-252-9160 and via email at [email protected]. Learn More on Oliver Engert's contact information.

Has Oliver Engert been buying or selling shares of Enovis?

Within the last three months, Oliver Engert has bought $56,545.00 in shares of Enovis stock. Most recently, on Wednesday, March 4th, Oliver Engert bought 250 shares of Enovis stock. The stock was acquired at an average cost of $25.10 per share, with a total value of $6,275.00. Following the completion of the transaction, the insider now directly owns 44,890 shares of the company's stock, valued at $1,126,739. Learn More on Oliver Engert's trading history.

Who are Enovis' active insiders?

Enovis' insider roster includes Benjamin Berry (CFO), Oliver Engert (Insider), Christopher Hix (CFO), John Kleckner (Insider), Patricia Lang (SVP), Damien Mcdonald (CEO), A. Perfall (Director), Daniel Pryor (EVP), Brady Shirley (COO), Bradley Tandy (SVP), Matthew Trerotola (CEO & Chairman), and Rajiv Vinnakota (Director). Learn More on Enovis' active insiders.

Are insiders buying or selling shares of Enovis?

During the last year, Enovis insiders bought shares 7 times. They purchased a total of 16,875 shares worth more than $506,135.05. During the last year, insiders at the sold shares 2 times. They sold a total of 1,665 shares worth more than $45,294.66. The most recent insider tranaction occured on March, 4th when insider Oliver Engert bought 250 shares worth more than $6,275.00. Insiders at Enovis own 2.7% of the company. Learn More about insider trades at Enovis.

Information on this page was last updated on 3/4/2026.

Oliver Engert Insider Trading History at Enovis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2026Buy250$25.10$6,275.0044,890View SEC Filing Icon  
3/3/2026Buy1,000$24.77$24,770.0044,640View SEC Filing Icon  
2/27/2026Buy1,000$25.50$25,500.0043,640View SEC Filing Icon  
See Full Table

Oliver Engert Buying and Selling Activity at Enovis

This chart shows Oliver Engert's buying and selling at Enovis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enovis Company Overview

Enovis logo
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $24.49
Low: $23.63
High: $24.61

50 Day Range

MA: $24.10
Low: $21.43
High: $29.75

2 Week Range

Now: $24.49
Low: $21.00
High: $40.69

Volume

911,050 shs

Average Volume

1,124,408 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46